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Introduction
Most cases of toxic myopathy are the consequence of drugs 
commonly used for therapeutic interventions.1 Muscle tissue is 
particularly vulnerable to drug-associated toxicity because of its 
relative abundance, high blood flow, and metabolic rate. One 
example of a toxic myopathy is colchicine-induced myopathy.2 
Colchicine is commonly used for the treatment of gouty arthritis, 
often at high initial doses. Colchicine myopathy is characterized 
by myalgias, muscle weakness, and occasional rhabdomyolysis.2 
In addition to myopathy, muscle tissue demonstrates the accu-
mulation of autophagic vacuoles.2 The mechanism of colchi-
cine-associated muscle toxicity is poorly understood. Colchicine 
destabilizes microtubules, which are required for both endosomal 
and autophagosomal maturation,3 the resultant accumulation of 
endosomal and autophagic debris has been previously proposed 
as the pathogenic mechanism for colchicine myopathy.3
Macroautophagy (autophagy) is the bulk degradation of cyto-
plasmic proteins and organelles.4 This process includes multiple 
steps, many of which require intact microtubules: (1) phagophore 
initiation and expansion, (2) autophagosome formation, and 
(3) autophagosome fusion with acidic lysosomes.5 Skeletal muscle 
is sensitive to stimuli that activate autophagic degradation, such 
as nutrient deprivation and exercise.6,7 In addition, several drugs 
such as rapamycin activate autophagy in mouse skeletal muscle.8 
If the accumulation of autophagic debris due to impaired micro-
tubule trafficking is indeed the pathogenic mechanism of col-
chicine-induced myopathy, it would be reasonable to expect that 
inducing autophagy in the setting of colchicine treatment should 
exacerbate the disease pathology/progression.
Statins (HMGCR [3-hydroxy-3-methylglutaryl-CoA reduc-
tase] inhibitors) are among the most commonly prescribed medi-
cations for the reduction of cholesterol,9 but their use is limited 
by muscle toxicity. Statin use has been associated with muscle 
pain, exercise intolerance, muscle weakness, and rhabdomyoly-
sis.10 Interestingly, the risk of statin-associated muscle toxicity 
increases with age and medication usage.10 In fact, many acute 
cases of muscle toxicity have been reported in patients concomi-
tantly taking statins and colchicine.11-20 Statins reportedly induce 
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colchicine treatment is associated with an autophagic vacuolar myopathy in human patients. The presumed 
mechanism of colchicine-induced myotoxicity is the destabilization of the microtubule system that leads to impaired 
autophagosome-lysosome fusion and the accumulation of autophagic vacuoles. Using the MTor inhibitor rapamycin 
we augmented colchicine’s myotoxic effect by increasing the autophagic flux; this resulted in an acute myopathy with 
muscle necrosis. in contrast to myonecrosis induced by cardiotoxin, myonecrosis induced by a combination of rapamycin 
and colchicine was associated with accumulation of autophagic substrates such as lc3-ii and sQsTM1; as a result, auto-
phagic vacuoles accumulated in the center of myofibers, where lc3-positive autophagosomes failed to colocalize with 
the lysosomal protein marker laMP2. a similar pattern of central lc3 accumulation and myonecrosis is seen in human 
patients with colchicine myopathy, many of whom have been treated with statins (hMGcr/hMG-coa reductase inhibi-
tors) in addition to colchicine. in mice, cotreatment with colchicine and simvastatin also led to muscle necrosis and lc3 
accumulation, suggesting that, like rapamycin, simvastatin activates autophagy. consistent with this, treatment of mice 
with four different statin medications enhanced autophagic flux in skeletal muscle in vivo. Polypharmacy is a known risk 
factor for toxic myopathies; our data suggest that some medication combinations may simultaneously activate upstream 
autophagy signaling pathways while inhibiting the degradation of these newly synthesized autophagosomes, resulting 
in myotoxicity.
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autophagy in vitro,21,22 lending credence to our hypothesis that 
active autophagy is the potential driving force behind colchicine-
induced muscle toxicity. To explore the impact of enhanced auto-
phagy in colchicine-induced myopathy, we evaluated muscle 
pathology in mice treated with rapamycin or simvastatin in the 
setting of colchicine.
Results
Rapamycin accelerates colchicine-induced muscle toxicity
Previous studies have evaluated the toxicity of colchicine in a 
rodent model and found that four weeks of intraperitoneal (i.p.) 
colchicine at a dose of 0.4 mg/kg/d caused a vacuolar myopathy.3 
Similarly, we found that i.p. colchi-
cine at the same dose for 40 d caused 
myopathy with rare vacuoles, and the 
accumulation of autophagic markers 
LC3 and SQSTM1 in mouse skeletal 
muscle (Fig. 1; see Fig. S1 for iso-
type control IgG staining). In some 
cases, LC3 and SQSTM1 colocal-
ized to the central region of a myofi-
ber (Fig. 1E). To investigate whether 
autophagy induction accelerated col-
chicine-induced muscle toxicity, we 
treated 24 mice for 10 d with vehicle, 
i.p. colchicine (0.4 mg/kg/d), i.p. 
rapamycin (10 mg/kg/d), or i.p. col-
chicine and rapamycin combination; 
following treatment, we analyzed the 
tibialis anterior (TA) and quadriceps 
muscles by routine histochemistry. 
TA and quadriceps muscles from 
mice treated for 10 d with colchicine 
or rapamycin alone appeared similar 
to control mouse muscle when visu-
alized via H&E or congo red, with 
no evidence of myopathic features 
(not shown). Therefore, in the case 
of colchicine, treatment periods lon-
ger than 10 d are necessary to induce 
the vacuolar changes seen in colchi-
cine myopathy. In contrast, mice 
treated with 0.4 mg/kg/d i.p. colchi-
cine and 10 mg/kg/d i.p. rapamycin 
for 10 d showed abnormal fibers 
with rare vacuolar structures, as evi-
denced by H&E, congo red, acid 
phosphatase, and succinate dehy-
drogenase staining (Fig. 2A–D). To 
confirm that the observed abnormal 
fibers were necrotic and that we 
had indeed accelerated the muscle 
toxicity induced by colchicine, we 
immunostained muscle sections with 
an antibody to complement c5b9, a 
marker of necrotic muscle fibers (Fig. 2E–H). The percentage 
of fibers that stained positive for c5b9 increased significantly in 
mice treated with both drugs compared with vehicle-, rapamy-
cin-, or colchicine-treated groups (Fig. 2I). These data suggest 
that enhancing autophagy with rapamycin augments the patho-
genesis of colchicine, leading to a necrotic autophagic myopathy.
Colchicine plus rapamycin-treated mouse muscle accumu-
lates autophagic structures
Given that we enhanced autophagosome biogenesis with 
rapamycin and at the same time blocked autophagosome deg-
radation with colchicine, we reasoned that the pathological 
changes seen in the skeletal muscle of colchicine plus rapamycin-
treated mice may be due to the accumulation of nondegraded 
Figure  1. chronic colchicine treatment leads to an autophagic vacuolar myopathy in mouse skeletal 
muscle. (A and B) h&e of Ta muscle from mice treated with (A) vehicle or (B) 0.4 mg/kg/d colchicine i.p. 
for 40 d. Black arrow denotes a vacuolated fiber. (C) Ta muscle similar to (B), immunostained with anti-
sQsTM1 or (D) anti-lc3 antibody. DaPi-stained nuclei are blue. White arrow denotes the accumulation of 
autophagic proteins. scale bar: 50 µm. (E) a single myofiber co-immunostained with antibodies to lc3; 
sQsTM1; and merged lc3 (green) and sQsTM1 (red). scale bar: 5 µm. The sarcolemma of some fibers is 
outlined.
©
20
13
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
www.landesbioscience.com autophagy 2117
Figure 2. rapamycin treatment augments pathology in a mouse colchicine myopathy model. histochemical analysis of Ta muscle from mice treated 
with colchicine (0.4 mg/kg/d) and rapamycin (10 mg/kg/d) for 10 d. (A and B) congo red, (C) acid phosphatase, and (D) succinate dehydrogenase staining 
demonstrate a myopathy with scattered necrotic fibers (arrows). (E and H) Ta muscle from (E) vehicle-, (F) rapamycin-, (G) colchicine- or (H) colchicine 
plus rapamycin-treated mice immunostained with an antibody to complement c5b9; arrows denote necrotic fibers. (I) Quantification of the percentage 
of c5b9-positive fibers per 20× field in muscle from mice treated with vehicle, rapamycin, colchicine or colchicine plus rapamycin for 10 d. *P < 0.05, the 
student unpaired t-test between treatment and control. n = 5/condition. scale bar: 50 µm.
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autophagosomes. To test this hypothesis, we immunoblotted TA 
muscle lysates from vehicle-, rapamycin-, colchicine- or colchi-
cine plus rapamycin-treated mice for the autophagic substrates 
SQSTM1 and LC3 (Fig. 3A). Upon phagophore formation, 
LC3-I can become lipidated and attach to the growing phago-
phore membrane as LC3-II.6 SQSTM1 and LC3-II levels were 
increased in colchicine-treated mice and to a greater extent in 
colchicine plus rapamycin-treated mouse muscle (Fig. 3A). 
Ubiquitinated proteins can be degraded via autophagy and are 
thus autophagic substrates.4 Consistent with this, the level of 
ubiquitinated proteins was elevated in colchicine plus rapamycin-
treated mouse muscle (Fig. 3A). In addition, two other autophagic 
Figure 3. autophagic substrates accumulate in the muscle of colchicine plus rapamycin-treated mice. (A) immunoblot using antibodies to lc3, sQsTM1, 
ubiquitinated proteins, BniP3, Becn1, and actin of Ta muscle from 3–4 mo old mice treated i.p. with vehicle, 10 mg/kg/d rapamycin (rapa), 0.4 mg/
kg/d colchicine (colch), or both drugs (colch+rapa) for 10 d. Blot is a representative of 3 independent experiments. (B) Quantitative Pcr analysis of rna 
from Ta muscle obtained from 3–4 mo old mice treated i.p. with vehicle (veh) or colchicine+rapamycin (colc+rap) for 10 d. Data are represented as fold 
change as compared with vehicle treatment. P values were obtained from the student unpaired t-test between treatment and control. n = 3/condition. 
(C) immunoblot using antibodies described above in addition to riPK1 kinase and GaPDh of Ta muscle injected with vehicle or 100 µl of 12 µM cardio-
toxin and harvested 2 d later. (D) Ta muscle from vehicle-, rapamycin-, colchicine-, or colchicine plus rapamycin-treated mice immunostained with an 
antibody to lc3 or sQsTM1. DaPi-stained nuclei are blue; the sarcolemma of some fibers is outlined. scale bar: 50 µm.
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proteins, BNIP3 and BECN1/ 
Beclin 1, were increased in TA mus-
cle lysates from mice treated with 
both colchicine and rapamycin com-
pared with mice treated with vehicle, 
rapamycin alone, or colchicine alone 
(Fig. 3A). The accumulation of auto-
phagic substrates such as LC3-II and 
SQSTM1 may not solely be caused 
by a decrease in their degradation but 
also as a result of enhanced transcrip-
tion of the corresponding genes. To 
test this, we performed quantitative 
RT-PCR expression analysis using 
total RNA isolated from TA muscle 
obtained from vehicle-treated and 
colchicine plus rapamycin-treated 
mice (Fig. 3B). Consistent with 
enhanced autophagosome biogen-
esis, the expression of MAP1LC3A, 
MAP1LC3B, and SQSTM1 were 
increased by ~3–4 fold (Fig. 3B). In 
addition, the expression of the lyso-
somal/endosomal protein LAMP1 
was increased by ~3 fold (Fig. 3B). 
In contrast, the expression of BNIP3 
was not different between groups 
(Fig. 3B).
We do not think that the accumu-
lation of autophagic substrates was a 
consequence of muscle necrosis, since 
muscle treated for two days with car-
diotoxin showed a modest change 
in LC3-II levels and a decrease 
in SQSTM1 levels (Fig. 3C). 
Immunohistochemical staining 
of LC3, SQSTM1, and BNIP3 in 
cardiotoxin-treated muscle demon-
strated that these autophagic mark-
ers were indeed altered in myofibers 
and not infiltrating cells (Fig. S2). 
Interestingly, BECN1 and BNIP3, as 
well as the necrotic signaling kinase 
RIPK1, were elevated after two days 
of cardiotoxin-induced muscle injury 
(Fig. 3C).
To define the localization of 
accumulated autophagic proteins in 
treated mouse muscle, we performed 
immunohistochemistry with antibod-
ies to LC3, SQSTM1, and BNIP3; in 
addition, we used an antibody to the lysosomal marker, LAMP2. 
All autophagic markers were increased in colchicine plus rapamy-
cin-treated mouse muscle when compared with muscle from the 
control, rapamycin-, and colchicine-treated mice (Fig. 3D and not 
shown). Scattered fibers showed an increase in SQSTM1-positive 
puncta in colchicine alone-treated muscle, but other autophagic 
markers were not increased above that seen with vehicle or rapamy-
cin treatment (Fig. 3D). Interestingly, these autophagic proteins 
were localized to the central region of myofibers (Fig. 4) rather 
than throughout the sarcoplasm, as seen in cardiotoxin-treated 
Figure 4. immunohistochemistry of Ta muscle from mice treated with vehicle (left panels) or colchicine 
and rapamycin (right panels) for 10 d using an anti-caV3/caveolin 3 antibody (green) and antibodies to 
lc3, laMP2, sQsTM1, and BniP3, all in red. scale bar: 50 µm.
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muscle (Fig. S2). To further characterize this, we performed 
several immunofluorescence colocalization studies. As expected, 
LC3 and LAMP2 did not colocalize in colchicine plus rapamycin-
treated mouse muscle, consistent with a failure in autophagosome-
lysosome fusion (Fig. 5A). In contrast, SQSTM1 colocalized 
with LC3, suggesting that the loading of autophagosomes was 
not impaired (Fig. 5B). Finally, 
SQSTM1 and ubiquitinated proteins 
strongly colocalized, indicating that 
association of SQSTM1 with ubiq-
uitinated substrates was not affected 
(Fig. 5C). Electron microscopy of 
similarly treated muscle demon-
strated the accumulation of vacuo-
lated structures, many of which had 
double membranes and contained 
cellular contents, consistent with 
autophagosomes. These structures 
were found within the central region 
of fibers between myofibrils (Fig. 5D 
and E).
Simvastatin-induced autophagy 
accelerates colchicine-induced mus-
cle toxicity
We previously reported the patho-
logical features of seven patients with 
colchicine-associated myopathy.23 
Polypharmacy is a well-established 
risk factor for colchicine muscle 
toxicity,2 and commonly prescribed 
drugs, such as the cholesterol-lower-
ing agents statins, are likely to play 
an important role. Indeed, two of 
seven patients in our original patient 
cohort (#22 and #25) and two of 
two patients diagnosed with col-
chicine myopathy since completion 
of that study (four of nine or 44% 
in total) were on both colchicine 
and a statin at the time of muscle 
biopsy. Immunohistochemical stain-
ing of these patients’ muscle biop-
sies showed a pattern of LC3 and 
SQSTM1 deposition in myofibers 
similar to that seen in colchicine 
plus rapamycin-treated mice (a rep-
resentative biopsy is shown in Fig. 6; 
compare with a muscle sample from 
control patient with no muscle dis-
ease, Fig. S3). A detailed quantifica-
tion of the percentage of LC3- and 
SQSTM1-immunopositive myo-
fibers in these human specimens 
has been previously reported.23 We 
therefore reasoned that statin medi-
cations, like rapamycin, may acceler-
ate and/or potentiate colchicine toxicity.
To test this, mice were divided into four treatment groups of 
six mice each: vehicle alone, 0.4 mg/kg/d colchicine, 10 mg/kg/d 
simvastatin, or both colchicine and simvastatin daily for 10 d. 
Following treatment, mice were sacrificed and TA and quadriceps 
muscles were analyzed via western blot, routine histopathology 
Figure  5. autophagic structures are centrally located in the myofibers of colchicine plus rapamycin-
treated mice. (A) a single myofiber co-immunostained with antibodies to lc3, laMP2, and merged lc3 
(green) and laMP2 (red). (B) a single myofiber co-immunostained with antibodies to lc3, sQsTM1, and 
merged lc3 (green) and sQsTM1 (red). (C) a single myofiber co-immunostained with antibodies to ubiq-
uitin, sQsTM1, and merged ubiquitin (green) and sQsTM1 (red). DaPi-stained nuclei are blue; the sarco-
lemma of a single fiber is outlined. scale bar: 5 µm. (D and E) electron microscopy images of Ta muscle 
from mice treated with colchicine and rapamycin. arrows denote autophagosomes. scale bar: 500 nm.
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and immunohistochemistry. Similar 
to the muscle pathology seen in mice 
treated with colchicine plus rapamy-
cin (Figs. 2 and 3) and human 
muscle pathology in patients treated 
with colchicine plus statin (Fig. 6), 
muscle from mice treated with col-
chicine plus simvastatin displayed 
myopathic features, with scattered 
necrotic fibers and LC3 accumula-
tion within the center of myofibers 
(Fig. 7B and D). This pattern was 
not seen in the other treatment 
groups, including the group treated 
with simvastatin alone (Fig. 7A and 
C). To confirm necrosis and quan-
tify the augmentation of colchicine 
toxicity by simvastatin, we immu-
nostained tissue with an antibody to 
c5b9 and quantified the percentage 
of positive fibers (Fig. 7E and F). 
Similar to colchicine plus rapamycin, 
colchicine plus simvastatin treatment 
resulted in an increase in necrotic 
fibers when compared with vehicle-, 
colchicine- or simvastatin-treated 
mice (Fig. 7G). Immunoblotting for 
autophagic substrates in colchicine 
plus simvastatin-treated mouse mus-
cle also demonstrated an increase 
in LC3-II, SQSTM1, and ubiquiti-
nated proteins when compared with any of the control groups 
(Fig. 7H); these data raise the possibility that, like rapamycin, 
statins activate autophagy.
Statins induce autophagy in mouse skeletal muscle
Previous studies have demonstrated that statins can induce 
autophagy in cell culture models of skeletal muscle,21,22 but it has 
not been established whether this occurs in vivo in mature skel-
etal muscle. To evaluate this, we treated mice with four different 
statin drugs (simvastatin, atorvastatin, lovastatin, and pravas-
tatin) for 7 d prior to isolating skeletal muscle and performing an 
immunoblot using an anti-LC3 antibody. To confirm that these 
drugs truly enhanced autophagic flux, we treated similar mice 
with 0.4 mg/kg colchicine on days 6 and 7 and then harvested 
TA muscles for immunoblot. LC3-II levels were unchanged in 
muscle from mice treated with statins alone when compared with 
muscle from vehicle-treated mice. As we have previously demon-
strated, there was accumulation of LC3-II in mice that received 
colchicine for 2 d, indicating a block in basal autophagy (Fig. 8A 
and B).8 Consistent with an increase in autophagic flux, skeletal 
muscle lysates from mice receiving a statin for 7 d and colchi-
cine on days 6 and 7 displayed increased accumulation of LC3-II 
when compared with the colchicine group, suggesting that statins 
enhance autophagic flux in vivo.8 The increase in flux is repre-
sented as the ratio of LC3-II to actin from four mice per condi-
tion (Fig. 8B).
Discussion
The myotoxic effect of colchicine is well known, but it has 
been difficult to pinpoint its pathogenic mechanism. The bulk 
of the relevant mechanisms proposed so far to explain colchicine-
induced muscle toxicity hinge on the disruption of the microtu-
bule network.2,3 In this study, we report data which support an 
expansion of the paradigm regarding the mechanism of colchicine-
induced muscle toxicity from mere disruption of the microtubule 
network to a functional and/or synergistic relationship between 
colchicine and autophagy induction. We have shown that mice 
treated for 10 d with both colchicine and autophagic inducers 
such as rapamycin or simvastatin display (1) increased accumu-
lation of autophagic substrates and ubiquitinated proteins; and 
(2) worsening of the colchicine-induced muscle pathology when 
compared with mice injected with colchicine alone. Thus, the 
emerging hypothesis is that colchicine-induced muscle toxicity 
is a result of autophagic vacuole build-up due to enhanced auto-
phagosome formation and impaired autophagic degradation; this 
possibility is supported by the fact that autophagic markers LC3 
and SQSTM1 robustly accumulate in the muscle of patients with 
colchicine-induced autophagic vacuolar myopathy.23
Colchicine and chloroquine have both been associated with 
toxic vacuolar myopathies.1 In the case of chloroquine, lysosomal 
de-acidification is the presumed mechanism by which auto-
phagic vacuoles accumulate and fail to be degraded.24 Previous 
Figure 6. accumulation of autophagic debris in the muscle biopsy from a patient concurrently treated 
with colchicine and a statin. h&e staining of frozen tissue (A) and toluidine blue staining of ePon-
embedded tissue (B) demonstrate disruption of the myofibrillary apparatus (arrows in A) and accumula-
tion of the vacuolated material (arrowheads in B) in the center of myofibers. immunohistochemistry for 
lc3 (C) or sQsTM1 (D) on formalin-fixed, paraffin-embedded tissue shows that vacuolated central areas 
contain lc3- and sQsTM1-positive autophagic material. scale bar: 20 µm.
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rodent models of chloroquine-induced myopathy have treated 
mice for several weeks with chloroquine to induce pathology.25 
Interestingly, dennervation of muscle hastens the development of 
an autophagic myopathy resulting in pathology over the course 
of days rather than weeks.25 Dennervation is a potent inducer 
of muscle atrophy and autophagy,8,26,27 an increase in autophagy 
in the setting of impaired autophagic degradation may explain 
Figure  7. simvastatin treatment aug-
ments pathology in a mouse colchicine 
myopathy model. h&e staining of Ta 
muscle from mice treated for 10 d with 
(A) simvastatin (10 mg/kg/d) or (B) col-
chicine (0.4 mg/kg/d) and simvastatin 
(10 mg/kg/d). (C and D) Ta muscle from 
(C) simvastatin- or (D) colchicine plus 
simvastatin-treated mice immunos-
tained with an antibody to lc3. (E and 
F) Ta muscle from (E) simvastatin- or 
(F) colchicine plus simvastatin-treated 
mice immunostained with an anti-
body to c5b9. open arrows denote 
necrotic fibers and closed arrows 
lc3-positive fibers. scale bar: 50 µm. 
(G) Quantification of the percentage 
of c5b9-positive fibers per 20× field 
in muscle treated with vehicle, simv-
astatin, colchicine, or colchicine plus 
simvastatin for 10 d. *P < 0.05, the 
student unpaired t-test between treat-
ment and control. n = 6/condition. 
(H) immunoblot of Ta muscle from 3–4 
mo old mice treated i.p. with vehicle, 
10 mg/kg/d simvastatin (simv), 0.4 mg/
kg/d colchicine (colch), or both drugs 
(colch+simv) for 10 d. Blot is a represen-
tative of 3 independent experiments.
the synergism between chloroquine 
treatment and dennervation in 
experimental models of chloroquine 
myopathy.
Many vacuolar myopathies are 
due to mutations in proteins asso-
ciated with lysosomal function and 
accumulate autophagic proteins 
within the myofiber similarly to the 
pathology seen in colchicine-associ-
ated myopathy. For example, Danon 
disease, Pompe disease, and X-linked 
myopathy with excessive autophagy 
all accumulate autophagic debris.28 
Whether the activation of autophagy 
is beneficial or detrimental for these 
diseases is not known. We recently 
demonstrated that enhancing auto-
phagy with rapamycin worsened the 
vacuolar pathology, protein aggre-
gate accumulation and weakness in 
a mouse model of inclusion body 
myopathy associated with Paget 
disease of the bone and fronto-tem-
poral dementia (IBMPFD).29 IBMPFD is caused by mutations 
in valosin containing protein, which is required for maturation 
of autophagosomes to autolysosomes.30 Interestingly, in the case 
of IBMPFD, X-linked myopathy with excessive autophagy and 
sporadic inclusion body myositis, MTORC1 activity is dimin-
ished, suggesting enhanced autophagosome formation.29,31,32 The 
©
20
13
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
www.landesbioscience.com autophagy 2123
current study lends further support to a mechanism of disease in 
which activation of autophagy drives the vacuolar pathology in 
some myopathies.
Statins initiate autophagy in cultured cells.21,33 The mecha-
nism by which statins induce autophagy likely relates to their 
mechanism of action within the HMGCR pathway. Specifically, 
depletion of geranylgeranyl diphosphate by statins and bisphos-
phonates can induce autophagy.21,34 Moreover, farnesyl trans-
ferase inhibitors and geranylgeranyl transferase inhibitors both 
induce autophagy in vitro.35,36 Our studies confirm these cell cul-
ture models and demonstrate that statins can effectively enhance 
autophagic flux in vivo in mouse skeletal muscle. In this context, 
it is worth noting that UCSF muscle pathology practice has seen 
a sharp increase in the number of colchicine and hydroxychloro-
quine myopathy cases in the last 5–6 y, coinciding with a large 
increase in statin use (based on a CDC survey entitled “Health, 
United States, 2010,” the percentage of statin-using adults [≥ 45 y 
of age] increased from 2% in the period of 1988–1994 to 25% in 
the period 2005–2008, and is likely even higher today).
Risk factors for statin muscle toxicity are higher dosages, 
concomitant use of certain drugs that can inhibit statin metabo-
lism, and more recently polymorphisms in the gene SLCO1B1/
OATP1B1 that encodes solute carrier organic anion transporter 
family, member 1B1, and mediates the uptake of various drugs 
including statins.37,38 It is conceivable that the accelerated muscle 
pathology seen in our studies is due to increased statin drug con-
centration in the setting of colchicine administration. However, 
based on the findings of our study, we propose that mutations or 
polymorphisms in genes within the autophagy pathway may also 
be risk factors for statin myotoxicity.
Materials and Methods
Antibodies and reagents for mouse studies
Antibodies for BECN1 (Cell Signaling Technologies, 3738), 
GAPDH (Cell Signaling Technologies, 2118), LAMP2 (Santa 
Cruz Biotechnology, sc-18822), BNIP3 (Abcam, ab10433), Actin 
(Sigma, A2066), LC3B (Sigma, L7543) for western blotting, LC3 
(Nanotools, 0231-100/LC3-5F10) for immunostaining, RIPK1/
RIP1 (BD Transduction Laboratories, 610458), c5b9 (Dako, 
M0777), and antibodies to SQSTM1 (Proteintech,18420-
1-AP) for western blotting, and to SQSTM1 (Sigma, P0067) for 
immunostaining were obtained from the indicated sources. For 
the autophagic assessment of necrotic fibers in Figure S2, the 
VECTOR M.O.M. immunodetection Kit Flourescein (Vector 
Laboratories, FMK-2001) was used to quench endogenous back-
ground IgG. Rapamycin (LC Laboratories R-5000) and cardio-
toxin (Sigma, C9759) were also purchased. Simvastatin (1965), 
atorvastatin (3776), lovastatin (1530), and pravastatin (2318) 
were obtained from TOCRIS.
Animals and drug treatments
All experiments were conducted using 3–4 mo old C57BL/6 
mice from Jackson Laboratory. Animal studies were approved by 
the Animal Studies Committee of Washington University School 
of Medicine. Upon arrival, mice were housed in a temperature-
controlled environment with 12 h light/dark cycles, where they 
Figure  8. statins enhance autophagic flux in mouse muscle in vivo. 
Five cohorts of mice were treated with vehicle or 1 of 4 different statin 
medications: simvastatin (simv), atorvastatin (atorva), lovastatin (lova) or 
pravastatin (prava) i.p., at a dosage of 10 mg/kg/d for 7 d. on days 6 and 7, 
some mice were also administered 0.4 mg/kg/d colchicine to block auto-
phagosome degradation. (A) immunoblots of mouse Ta muscle lysates 
using antibodies for lc3 and actin. (B) Densitometric quantification of 
lc3-ii/actin from immunoblots. (+) indicates with colchicine treatment. 
*P < 0.05, student unpaired t-test between treatment and colchicine 
groups. n ≥ 4 mice/condition.
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received food and water ad libitum. All drugs were injected intra-
peritoneally. Rapamycin was dissolved in 100% ethanol at 62.5 
mg/ml, stored at −20 °C, and diluted to 2.5 mg/ml in vehicle 
(5% PEG 400, 5% Tween 80, and 4% ethanol) just before injec-
tion. Colchicine was dissolved in water, stored at −20 °C as a 
stock solution at a concentration of 4 mg/ml, and diluted to 0.1 
mg/ml before injection. Simvastatin, atorvastatin, lovastatin, and 
pravastatin were administered at a dose of 10 mg/kg body weight. 
Simvastatin and lovastatin were dissolved in 100% ethanol and 
stored at −20 °C as stocks; on the day of experiment, they were 
diluted with PBS immediately prior to injection. Atorvastatin 
was dissolved in DMSO and stored as stock solution, which was 
diluted with PBS immediately prior to injection. Pravastatin was 
dissolved in water. For all drug treatments, control mice received 
equal volumes of respective vehicles. Mice were subjected to i.p. 
injection of both rapamycin (10 mg/kg body weight) and colchi-
cine (0.4 mg/kg body weight) daily for 10 d. Age-match litter-
mates were injected with vehicle (5% Tween 80, 5% polyethylene 
glycol, and 4% ethanol), rapamycin alone, or colchicine alone 
as controls. Similar experiments were performed with simvas-
tatin (10 mg/kg body weight) in place of rapamycin. Cardiotoxin 
(from Naja mossabica mossambica) was dissolved in water and 
stored at -20 °C as stock solution, which was diluted in PBS to a 
working concentration of 12 µM prior to experiment. For each 
mouse, tibialis anterior muscles were injected with 100 µL of 
12 µM cardiotoxin and muscles were harvested 2 d later.
Western blotting
Muscle tissues were homogenized using RIPA lysis buffer 
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% 
Na-deoxycholate, 1 mM EDTA) supplemented with protease 
inhibitor cocktail (Sigma-Aldrich, s8820-20TAB) and then cen-
trifuged at 14,000 g for 10 min. Protein concentrations were deter-
mined using BCA protein assay kit (Thermo Fisher Scientific, 
23225). Aliquots of lysates were solubilized in Laemmli sample 
buffer and equal amounts of proteins were separated by 12% 
SDS-PAGE. Proteins were transferred to nitrocellulose mem-
brane and the membrane was blocked with 5% nonfat dry milk 
in phosphate-buffered saline (PBS) for 1 h. The membrane was 
then incubated with primary antibodies in 5% nonfat dry milk 
overnight at 4 °C; after incubation with the appropriate second-
ary antibody conjugated with horseradish peroxidase, enhanced 
chemiluminescence (ImmunoPure, 31430) was used for protein 
detection. If necessary, blots were stripped using Re-blot strong 
solution (Millipore, 2504) and reprobed with the appropriate 
antibodies. Autoradiographs of immunoblots were scanned using 
an Epson 636 Expression scanner; immunoblots were obtained 
using the G:BoxChemi XT4, Genesys Version 1.1.2.0 (Syngene).
Gene expression analyses
Total RNA was isolated from TA muscle with SV Total RNA 
isolation kit (Promega, Z3100) according to the manufacturer’s 
instructions. The concentration and quality of the total RNA 
isolated was determined using a Nanodrop spectrophotometer. 
cDNA was synthesized using the RT1 First Strand kit (Qiagen, 
330401). Gene expression levels were analyzed by real-time PCR 
on an Applied Biosystems model 7500 (software v2.0.5) using the 
RT1 SYBER Green ROX qPCR mastermix (Qiagen, 330522) 
and the mouse autophagy RT1 Profiler PCR array (Qiagen, 
330231 PAMM-084ZA), which contains primers for the expres-
sion of 84 autophagy genes arranged in a staggered format. Data 
were normalized to the average of 4 housekeeping genes, Gapdh, 
Actb/β-actin, B2m/β2-microglobulin, and Gusb/β-glucoronidase 
and expressed in terms of 2-ΔΔCT.
Histochemistry, immunohistochemistry, and electron 
microscopy
Isolated muscle was mounted using tragacanth gum (Sigma, 
G1128) and quick frozen in liquid nitrogen-cooled 2-methylbu-
tane. Samples were stored at −80 °C until sectioning into 10-µm 
sections. H&E, congo red, acid phosphatase, and succinate 
dehydrogenase staining was performed as previously described.39 
Briefly, muscle sections were affixed to slides incubated for 10 
min in ice-cold acetone, mounted with Prolong Gold + DAPI 
(Invitrogen, P36931), and examined using a fluorescence micro-
scope (Nikon 80i upright+ and Roper Scientific EZ mono-
chrome CCD camera with deconvolution software analysis [NIS 
Elements, Nikon]). Nonfluoresent images were taken with a 5 
megapixel color CCD (Nikon). For electron microscopy, TA 
muscle was harvested, rinsed briefly in PBS and then placed 
immediately in Karnovsky fixative40 at 4 °C for 24 h. Fixed 
muscle was embedded in plastic and sectioned for EM imag-
ing. Images were taken using a Jeol 1400 and a Gatan Orius 832 
Digital Camera. Image processing and analysis were done with 
(NIS Elements 4.0) software and Adobe Photoshop.
Quantification of necrotic fibers
The percentage of c5b9-positive fibers was quantified per 20× 
field. Twenty randomly selected microscopy fields from 10 TA 
muscles from 5 mice/condition were selected and the total num-
ber of myofibers and the number of immunoreactive fibers were 
counted and expressed as a percentage.
Human subjects
Study design was reviewed and approved by the University 
of California San Francisco Committee on Human Research; 
the informed consent requirement was waived given the nonin-
vasive nature of the study and a minimal potential for harm to 
study participants. Immunoperoxidase staining for LC3 (mouse 
monoclonal antibody, clone 5F10, Nanotools, 0231-100) and 
SQSTM1 (guinea pig polyclonal antibody, Progen Biotechnik, 
GP62) was performed on formalin-fixed, paraffin-embedded tis-
sue samples using the Ventana Benchmark XT automated slide 
preparation system as described previously.23 Images were taken 
with a DP72 digital camera on a BX41 bright-field light micro-
scope using cellSens Entry 1.6 software (all by Olympus) and 
were edited with Adobe Photoshop CS5 Version 12.1.32.
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